%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3crect%20x='10.3'%20y='14'%20style='&st5;'%20width='5'%20height='4.4'/%3e%3crect%20x='10.3'%20y='12'%20style='&st5;'%20width='11.4'%20height='1'/%3e%3crect%20x='16.4'%20y='14'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='15.8'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='17.5'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='19.3'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='10.3'%20y='19.3'%20style='&st5;'%20width='5'%20height='0.9'/%3e%3cg%3e%3cpath%20style='&st5;'%20d='M22.6,22.3H9.4c-0.6,0-1.2-0.5-1.2-1.2v-10c0-0.6,0.5-1.2,1.2-1.2h13.1c0.6,0,1.2,0.5,1.2,1.2v10%20C23.7,21.7,23.2,22.3,22.6,22.3z%20M9.4,10.8c-0.1,0-0.3,0.1-0.3,0.3v10c0,0.1,0.1,0.3,0.3,0.3h13.1c0.1,0,0.3-0.1,0.3-0.3v-10%20c0-0.1-0.1-0.3-0.3-0.3H9.4z'/%3e%3c/g%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Clinical Trial News
10/30/2026
BreakingClinical TrialMyopiaRegulation
US FDA Advisory Panel Meets to Review Sydnexis’ Rejected Myopia Drop, Hear Public Comments
The US FDA Dermatologic and Ophthalmic Drugs Advisory Committee held a meeting and open public hearing on Oct. 30 in Silver Spring, Maryland, to review the new drug application (NDA) for Sydnexis’ ...
10/30/2026
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Gives Green Light to Trial of Opus’ Gene Therapy for RDH12-LCA
Opus Genetics announced on Oct. 21 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of OPGx-RDH12, a gene therapy ca...
10/23/2026
BreakingClinical TrialIndustryPharmaRetina
EyePoint to Slash Workforce, End Pivotal Wet AMD Trials After Second Miss for Duravyu
EyePoint announced Oct. 19 that it would cut its workforce by 53 percent and end the Phase III trials for Duravyu in wet age-related macular degeneration (AMD) early after the LUCIA study failed to...
10/21/2026
Cell TherapyClinical TrialCornealGene TherapyNewsletterRetinaThyroid Eye Disease
Clinical Trial Updates for Ophthalmic Candidates, October 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
10/21/2026
BiosimilarsCell TherapyChinaClinical TrialCornealDealsDiagnosticFundingGene TherapyGlaucomaIndustryMyopiaNewsletterOptometryRegulationRetinaSurgical
October 2026 Ophthalmic News Briefs
Sagent Pharmaceuticals, of Schaumburg, Illinois, announced Sept. 22 the US launch of Zyogreen, the first FDA-approved ready-to-use indocyanine green (ICG) injection in the US. Sagent said conventio...
10/16/2026
BreakingClinical TrialPharmaRetina
Merck Sees Mixed Results at One Year in Pivotal Trial of Remigromig in DME
Merck presented one-year results from remigromig’s pivotal Phase IIb/III BRUNELLO trial at the 2026 meeting of the American Academy of Ophthalmology (AAO), held Oct. 10-12 in New Orleans, Louisiana...
10/9/2026
BreakingClinical TrialPharmaRegulationRetina
US FDA Gives Green Light to Trial of Surrozen’s DME Candidate
Surrozen announced on Oct. 2 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of SZN-8141, a bifunctional Wnt agonis...
10/2/2026
BreakingCell TherapyChinaClinical TrialRetina
iRegene’s RP Cell Therapy Candidate Gets Green Light for Clinical Trials in China, US
China’s iRegene Therapeutics announced Sept. 29 that its cell therapy candidate targeting retinitis pigmentosa (RP) gained authorization from regulators to enter clinical trials in both China and t...
9/22/2026
Clinical TrialNewsletterPharmaRegulationRetina
EyePoint’s Duravyu Misses Primary Visual Acuity Endpoint in Phase III Wet AMD Trial
EyePoint Pharmaceuticals reported Aug. 17 that Duravyu (vorolanib intravitreal insert) missed its primary visual acuity endpoint in topline results from the Phase III LUGANO trial in wet age-relate...
9/22/2026
Cell TherapyClinical TrialGene TherapyNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, September 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
9/18/2026
BreakingClinical TrialDeviceGlaucomaRegulationSurgical
US FDA Gives Green Light to Trial of Ciliatech’s Intercil Uveal Spacer for Glaucoma
France’s Ciliatech announced Sept. 8 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a feasibility study of its Interci...
9/11/2026
BreakingClinical TrialCorneal
European Consortium Studies Gene-Silencing Eye Drops Targeting Corneal Vascularization
Two studies underway at the University of Cologne in Germany will test whether a new class of eye drops silencing the insulin-receptor substrate 1 (IRS1) gene can slow the blood vessel growth that ...
8/28/2026
BreakingClinical TrialDry EyePharma
Bausch + Lomb Advancing Dual-Action Dry Eye Drop, Ocular Surface Pain Candidate
Bausch + Lomb reported Aug. 24 that it would advance two of its topical ocular pipeline candidates based on clinical trial results. The company’s dual-action dry eye drop candidate—combining lifite...
8/21/2026
BreakingClinical TrialRetina
EyePoint’s Duravyu Misses Primary Visual Acuity Endpoint in Phase III Wet AMD Trial
EyePoint Pharmaceuticals reported Aug. 17 that Duravyu (vorolanib intravitreal insert) missed its primary visual acuity endpoint in topline results from the Phase III LUGANO trial in wet age-relate...
8/20/2026
Clinical TrialGlaucomaIndustryNewsletterPharma
Bausch + Lomb Drops Glaucoma Neuroprotection Program after Phase II Failure
Bausch + Lomb announced July 10 that it would discontinue development of a neuroprotective eye drop candidate for glaucoma, citing Phase II results in which BL1107, a prodrug of brimonidine tartrat...
8/20/2026
CataractChinaClinical TrialCornealDealsDiagnosticDry EyeFundingGene TherapyGlaucomaIOLNewsletterPharmaRetinaSurgical
Tarsus Leads Latest Fundraising with $125 Million Private Placement
Tarsus Pharmaceuticals led recent ophthalmic fundraising efforts with a $125 million private placement for clinical development and commercial activities. Financing announced in the past four weeks...
8/20/2026
Clinical TrialGlaucomaNewsletterRegulationSurgical
Glaukos Changes US Regulatory Pathway for PreserFlo, Completes Enrollment in 510(k) Study
Glaukos reported July 27 that it had completed patient enrollment in a 510(k) pivotal study for the PreserFlo MicroShunt. The glaucoma drainage device is implanted ab externally to increase outflow...
8/20/2026
Clinical TrialGene TherapyGlaucomaMyopiaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, August 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
8/20/2026
Clinical TrialEmergingGene TherapyNewsletterOcular CancerRetina
Emerging Companies Pursuing Ophthalmic Indications, August 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
8/14/2026
BreakingChinaClinical TrialRetina
US FDA Gives Green Light to Trial of Ractigen’s saRNA Candidate in PVR
China’s Ractigen Therapeutics reported on July 31 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I clinical trial of ...
7/21/2026
CataractClinical TrialDry EyeGene TherapyNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, July 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
7/17/2026
BreakingClinical TrialGlaucomaRetina
Bausch + Lomb Drops Glaucoma Neuroprotection Program after Phase II Failure
Bausch + Lomb announced July 10 that it would discontinue development of a neuroprotective eye drop candidate for glaucoma, citing Phase II results in which BL1107, a prodrug of brimonidine tartrat...
6/18/2026
Clinical TrialNewsletterRetina
Oculis Scraps DME Eye Drop Program after Missing Phase III Endpoints
Swiss company Oculis reported May 29 that it would not pursue US FDA approval for OCS-01, its dexamethasone eye drop candidate targeting diabetic macular edema (DME), after the primary endpoint of ...
6/18/2026
AIClinical TrialDealsEyeceleratorFundingMeetingNewsletterRegulation
Eyecelerator@ARVO and All Access Saturday Look at Business Side of Developing Therapeutics
May 1 marked the start of a new era for Eyecelerator, the organizer of ophthalmology innovation business conferences. It was the first time Eyecelerator was officially part of ARVO (Association for...
6/18/2026
Clinical TrialGene TherapyMeetingNewsletterRegulationRetina
2026 ARVO Keynote Speaker Says ‘Age of RNA’ Has Arrived
Thomas Cech, PhD, declared the 21st century “the age of RNA” during his opening keynote address at the 2026 ARVO meeting. Sally Temple, PhD, used the closing keynote to talk about the future of ste...
6/18/2026
AIClinical TrialDiagnosticDigitalMeetingNewsletter
AI Sessions at 2026 ARVO Meeting Move Past the Hype
The conversation around AI in ophthalmology has evolved over the past three years. The emphasis at the 2026 ARVO meeting and the Focus A-Eye Summit was on how to bridge the gap between innovation a...
6/18/2026
Clinical TrialCornealDry EyeGene TherapyGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, June 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
6/18/2026
AIAllergyAmblyopiaCataractClinical TrialDealsDiagnosticIOLIndustryLaserMicroscopesMyopiaNewsletterOptometryPharmaRegulationRetinaSingle-UseSurgical
June 2026 Ophthalmic News Briefs
UK-based Rayner announced June 1 the launch of Ophteis Cohesive, a new OVD formulated with a high molecular weight to optimize space creation and ease of removal. Ophteis Cohesive is packaged at 1....
6/5/2026
BreakingClinical TrialPharmaRetina
Oculis Scraps DME Eye Drop Program after Phase III Failure
Swiss company Oculis reported May 29 that it would not pursue US FDA approval for OCS-01, its dexamethasone eye drop candidate targeting diabetic macular edema (DME), after the primary endpoint of ...
5/14/2026
CataractClinical TrialCornealGene TherapyIOLNewsletterRetinaSurgicalThyroid Eye Disease
Clinical Trial Updates for Ophthalmic Candidates, May 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
5/8/2026
BreakingClinical TrialRegulationRetina
US FDA Accepts Opus’ LCA5 Gene Therapy Candidate into New Rare Disease Program
Opus Genetics announced May 4 that the US FDA had accepted OPGx-LCA5, a gene therapy candidate targeting Leber congenital amaurosis type 5, into the new Rare Disease Evidence Principles (RDEP) prog...
5/1/2026
BreakingCataractClinical TrialIOLPharma
US FDA Gives Green Light to Trial of LayerBio’s OcuRing-K for Post-op Inflammation and Pain
Israel’s PRF Technologies and its majority-owned subsidiary LayerBio reported on April 28 that the US FDA had signed off on their investigational new drug (IND) application, allowing LayerBio to pr...
4/21/2026
Cell TherapyClinical TrialCornealGene TherapyNewsletterRetinaThyroid Eye Disease
Clinical Trial Updates for Ophthalmic Candidates, April 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
4/21/2026
ChinaClinical TrialEmergingGlaucomaIOLNewsletterProsthesisRetina
Emerging Companies Pursuing Ophthalmic Indications, April 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
4/21/2026
BiosimilarsCataractCell TherapyChinaClinical TrialCornealDiagnosticDigitalDry EyeIOLIndiaIndustryMicroscopesNewsletterPharmaRegulationRetina
April 2026 Ophthalmic News Briefs
Swiss ophthalmic diagnostics company Haag-Streit announced March 31 the global launch of its Metis 3D Digital Heads-Up Module (Metis HU). The system was launched in the US in October 2025. Metis HU...
4/10/2026
BreakingClinical TrialDeviceRegulationRetina
US FDA Gives Green Light to Trial of i-Lumen’s Bioelectric Stimulation Device for Dry AMD
i-Lumen Scientific announced March 31 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a pivotal trial of its bioelectri...
4/3/2026
BreakingCataractClinical TrialIOLRegulationSurgical
US FDA Gives Green Light to Trial of Long Bridge’s Prosthetic Capsular Bag
Long Bridge Medical announced March 26 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a pivotal trial of LensOne, its ...
3/27/2026
BreakingChinaClinical TrialRetina
Innovent Reports Positive Phase III Results for Extended-Dosing Retinal Candidate
China’s Innovent Biologics reported March 23 that IBI302 (efdamrofusp alfa), its extended-dosing retinal candidate, met its primary visual acuity endpoint at week 52 in the Phase III STAR study. IB...
3/24/2026
Clinical TrialCornealGene TherapyGlaucomaMyopiaNewsletterPharmaRetina
Clinical Trial Updates for Ophthalmic Candidates, March 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
3/24/2026
Clinical TrialNewsletterPharmaRegulation
US FDA Will Drop Two-Study Requirement for New Drug Approvals
The US FDA plans to drop its longtime standard of requiring two rigorous studies to win approval for new drugs, according to a journal article published Feb. 18. Going forward, the agency’s “defaul...
3/24/2026
BiosimilarsCataractClinical TrialCornealDealsDiagnosticEuropeFundingGlaucomaIOLIndustryNewsletterPresbyopiaRefractiveRegulationRetinaStudySurgical
March 2026 Ophthalmic News Briefs
STAAR Surgical announced Feb. 17 that the US FDA had approved an expanded age indication for Evo and Evo+ implantable Collamer lenses (ICLs), extending their use from patients 21 to 45 years old to...
3/6/2026
BreakingCataractClinical TrialPharma
US FDA Gives Green Light to Phase III Trial of Harrow’s Triesence for Post-op Inflammation and Pain
Nashville, Tennessee-based Harrow reported on March 3 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase III trial of Tri...
3/6/2026
BreakingCell TherapyClinical TrialRegulationRetina
US FDA Gives Green Light to Phase I/II Trial of Sanaregen’s Retinal Cell Therapy Candidate
Sanaregen Vision Therapeutics reported March 3 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of its retin...
2/27/2026
AllergyBreakingClinical TrialPharmaRegulation
US FDA Gives Green Light to Phase II/III Trial of NexEos Bio’s Vernal Keratoconjunctivitis Candidate
NexEos Bio, of Malvern, Pennsylvania, reported on Feb. 19 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase II/III trial...
2/27/2026
BreakingClinical TrialPharmaPresbyopiaRegulation
US FDA Gives Green Light to Phase II Trial of Cloudbreak’s Presbyopia Drop Candidate
The financial website TipRanks reported on Feb. 15 that the US FDA had signed off on Cloudbreak Pharma’s investigational new drug (IND) application, allowing the company to proceed with a Phase II ...
2/23/2026
CataractClinical TrialCornealGene TherapyGlaucomaIOLNewsletterPharmaRetina
Clinical Trial Updates for Ophthalmic Candidates, February 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
2/23/2026
Clinical TrialNewsletterPharmaRegulationRetina
Ocular Therapeutix Reports Positive Results for Axpaxli vs. Eylea in Phase III Wet AMD Trial
Ocular Therapeutix reported on Feb. 17 positive topline results in the SOL-1 Phase III superiority trial of Axpaxli vs. Eylea (aflibercept) in wet age-related macular degeneration (AMD). Axpaxli, a...
2/23/2026
CataractClinical TrialCornealDealsDiagnosticDry EyeIOLNewsletterRefractiveRegulationRetinaSurgicalUveitis
February 2026 Ophthalmic News Briefs
Belgian investment company Groupe Bruxelles Lambert (GBL) reported Feb. 9 that it would invest 500 million euros (US $594 million, calculated on Feb. 11, 2026) in UK-based ophthalmic company Rayner...
2/20/2026
BreakingClinical TrialPharmaRegulation
US FDA Will Drop Two-Study Requirement for New Drug Approvals
The US FDA plans to drop its longtime standard of requiring two rigorous studies to win approval for new drugs, according to a journal article published Feb. 18. Going forward, the agency’s “defaul...
2/20/2026
BreakingClinical TrialPharmaRegulationRetina
Ocular Therapeutix Reports Positive Results for Axpaxli vs. Eylea in Phase III Wet AMD Trial
Ocular Therapeutix reported on Feb. 17 positive topline results in the SOL-1 Phase III superiority trial of Axpaxli vs. Eylea (aflibercept) in wet age-related macular degeneration (AMD). Axpaxli, a...
2/6/2026
BreakingCell TherapyClinical TrialRegulationRetina
US FDA Gives Green Light to Trial of Life Bio’s Cell Rejuvenation Candidate in Optic Neuropathies
Life Biosciences reported on Jan. 28 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I trial of ER-100, a cell rejuven...
2/6/2026
BreakingClinical TrialGene TherapyRetina
Opus Launches Trial in Abu Dhabi for RP Gene Therapy Candidate
Opus Genetics announced Jan. 27 that it had launched a clinical trial in Abu Dhabi, the capital of the United Arab Emirates, for its gene therapy candidate targeting MERTK-related retinitis pigment...
1/30/2026
BreakingClinical TrialRegulationUveitis
US FDA Gives Green Light to Phase II Trial of Novaliq’s Topical Uveitis Candidate
Germany’s Novaliq reported on Jan. 26 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase II trial of NOV05, its topical, ...
1/30/2026
BreakingClinical TrialCornealRegulation
US FDA Authorizes Compassionate Use of Urcosimod for Neuropathic Corneal Pain
London’s Okyo Pharma announced Jan. 23 that the US FDA had authorized a compassionate-use request for a single patient with severe neuropathic corneal pain to be treated with urcosimod (0.05%). The...
1/21/2026
Clinical TrialNewsletterRegulationRetina
Ocular Therapeutix Takes Cue from FDA, Will Submit NDA for Axpaxli After Single Phase III Trial
Ocular Therapeutix announced Dec. 8 that it planned to submit a new drug application (NDA) to the US FDA for Axpaxli in wet age-related macular degeneration (AMD) if it sees positive one-year data ...
1/21/2026
Clinical TrialNewsletterRegulationUveitis
VivaVision Needs Single US Phase III Trial for Uveitis NDA, FDA Says
VivaVision Biotech reported Jan. 6 that minutes from its meeting with the US FDA confirm that its ongoing Phase III study in China can serve as one of the two pivotal trials required to support a U...
1/21/2026
Clinical TrialNewsletterThyroid Eye Disease
Argenx Pulls Plug on Thyroid Eye Disease Program on Recommendation of Data Monitors
Dutch drugmaker Argenx reported Dec. 15 that it would discontinue the Phase III program for subcutaneous efgartigimod in moderate to severe thyroid eye disease (TED). An independent data monitoring...
1/21/2026
AllergyClinical TrialCornealGene TherapyNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates , January 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
1/21/2026
AAOClinical TrialCornealDealsGene TherapyGenericsIndustryNewsletterRegulationRetinaThyroid Eye Disease
January 2026 Ophthalmic News Briefs
Italy-based NTC reported Dec. 10 that it had completed its acquisition of Pharmathen’s ophthalmology business. No financial details were provided. NTC said the move gives it a global portfolio of g...
1/16/2026
BreakingClinical TrialPresbyopiaRefractiveRegulation
US FDA Gives Green Light to Trial of Allotex’ Tissue Implant for Presbyopia
Allotex announced Jan. 8 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a trial of Allo-1, its tissue implant technolo...
1/9/2026
BreakingChinaClinical TrialCornealGene TherapyRegulation
US FDA Gives Green Light to Trial of GenEdit Bio’s Corneal Gene-Editing Candidate
GenEditBio reported on Jan. 5 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of GEB-101, its gene-editing ...
1/9/2026
BreakingChinaClinical TrialRegulationRetina
VivaVision Needs Single US Phase III Trial for Uveitis NDA, FDA Says
VivaVision Biotech reported Jan. 6 that minutes from its meeting with the US FDA confirm that its ongoing Phase III study in China can serve as one of the two pivotal trials required to support a U...
1/2/2026
BreakingClinical TrialCornealDry EyeRegulation
US FDA Gives Green Light to Trial of Viatris’ Gene Therapy Candidate for NK
Viatris reported on Dec. 18 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of MR-146, a gene therapy candi...
1/2/2026
BreakingClinical TrialRetina
USC Roski Eye Takes Part in Phase IIb Trial of RPE Patch Candidate for GA
Researchers at the University of Southern California Roski Eye Institute reported Dec. 17 that they are taking part in a Phase IIb trial of Regenerative Patch Technologies’ retinal pigmented epithe...
12/26/2025
BreakingClinical TrialIndustryThyroid Eye Disease
Argenx Pulls Plug on Thyroid Eye Disease Program on Recommendation of Data Monitors
Dutch drugmaker Argenx reported Dec. 15 that it would discontinue the Phase III program for subcutaneous efgartigimod in moderate to severe thyroid eye disease (TED). An independent data monitoring...
12/19/2025
BreakingClinical TrialRegulationRetina
Ocular Therapeutix Takes Cue from US FDA, Will Submit NDA for Axpaxli After Single Phase III Trial
Ocular Therapeutix announced Dec. 8 that it planned to submit a new drug application (NDA) to the US FDA for Axpaxli in wet age-related macular degeneration (AMD) if it sees positive one-year data ...
12/16/2025
Clinical TrialCornealNewsletter
Precise Bio Implants World’s First 3D Bioprinted Cornea in Patient in Israel
Precise Bio announced Nov. 19 that the first patient had been treated with PB-001, the company’s 3D bioprinted corneal implant candidate, in a Phase I clinical trial. The legally blind patient was ...
12/16/2025
Clinical TrialCornealNewsletterRegulation
US FDA Gives Green Light to Trial of EyeYon’s EndoArt Artificial Corneal Implant
Israel’s EyeYon Medical announced Dec. 8 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a trial of EndoArt, a syntheti...
12/16/2025
Clinical TrialGene TherapyGlaucomaMIGSNewsletterRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, December 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
12/12/2025
BreakingClinical TrialCornealRegulation
US FDA Gives Green Light to Trial of EyeYon’s EndoArt Artificial Corneal Implant
Israel’s EyeYon Medical announced Dec. 8 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a trial of EndoArt, a syntheti...
12/12/2025
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Gives Green Light to Trial of Zhongmou’s Optogenetic Therapy for RP
China’s Zhongmou Therapeutics announced Nov. 27 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of ZM-02, t...
11/19/2025
Clinical TrialCornealGene TherapyGlaucomaIOLMIGSNewsletterRetinaUveitis
Clinical Trial Updates for Ophthalmic Candidates, November 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
11/19/2025
AIBiosimilarsChinaClinical TrialDealsDiagnosticEuropeGene TherapyIndustryNewsletterPerimetryPresbyopiaRegulationRetinaThyroid Eye DiseaseUveitis
November 2025 Ophthalmic News Briefs
VEO Ophthalmics announced Oct. 16 that the VisionOne VR Visual Field platform is now available in the US through a strategic partnership with Switzerland’s PeriVision. No financial details about th...
11/7/2025
BreakingClinical TrialGene TherapyRegulationRetina
FDA Clears Way for US Patient to Receive GenSight’s Lumevoq for LHON
France’s GenSight Biologics announced Oct. 30 that the FDA had granted permission for a single patient in the US to be treated with GS010, also known as Lumevoq, GenSight’s intravitreal gene therap...
11/7/2025
BreakingClinical TrialPharmaRetinaUveitis
Roche Reports Mixed Phase III Data for Vamikibart in Uveitic Macular Edema
Swiss drugmaker Roche reported on Oct. 16 mixed Phase III results for vamikibart, an IL-6 inhibitor being developed to address inflammation in uveitic macular edema (UME). Vamikibart, if approved, ...
10/23/2025
Clinical TrialCornealIndustryNewsletter
Kala to Shut Down Eye Drop Program for Corneal Defect After Phase IIb Failure
Kala Bio reported Sept. 29 that it would cease development of lead asset KPI-012 and end its mesenchymal stem cell secretome program after the eye drop candidate failed to reach its primary endpoin...
10/23/2025
Clinical TrialGene TherapyGlaucomaIOLLow VisionNewsletterPharmaRetina
Clinical Trial Updates for Ophthalmic Candidates, October 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
10/17/2025
BreakingClinical TrialDeviceGlaucomaMIGS
US FDA Gives Green Light to Trial of Avisi’s VisiPlate Aqueous Shunt for Glaucoma
Avisi Technologies announced Oct. 14 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a trial of the VisiPlate aqueous s...
10/17/2025
BreakingClinical TrialIndustryPharmaRetina
Ashvattha Names Bob Dempsey as Interim CEO
Ashvattha Therapeutics, of Redwood City, California, announced Oct. 14 that it had appointed Robert J. Dempsey as interim chief executive officer. The move follows the company’s release of positive...
10/10/2025
BreakingClinical TrialPharmaRegulationRetina
Oculis Accelerates Privosegtor Toward Pivotal Trials in Neuro-ophthalmology
Swiss company Oculis announced Oct. 6 that it will advance Privosegtor into a pivotal program for two indications in neuro-ophthalmology following a positive meeting with the US FDA. Privosegtor is...
10/10/2025
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Gives Green Light to Phase I/II Trial of Complement’s GA Gene Therapy Candidate
Complement Therapeutics announced Oct. 8 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of CTx001, a gene ...
10/3/2025
BreakingClinical TrialCorneal
Kala to Shut Down Eye Drop Program for Corneal Defect After Phase IIb Failure
Kala Bio reported Sept. 29 that it would cease development of lead asset KPI-012 and end its mesenchymal stem cell secretome program after the eye drop candidate failed to reach its primary endpoin...
9/22/2025
Cell TherapyClinical TrialGlaucomaNewsletterRefractiveRetina
Clinical Trial Updates for Ophthalmic Candidates, September 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
9/22/2025
Clinical TrialEuropeIndustryMeetingNewsletterRegulationRetina
Two European Retina Innovation Meetings, Two Audiences
Euretina once again scheduled its European Innovation Spotlight to go head-to-head with the Ophthalmology Futures Retina Forum. Both were held Sept. 3 in Paris, France. The two events seem similar ...
9/22/2025
BiosimilarsClinical TrialCornealDealsDiagnosticDry EyeEuropeFundingGene TherapyGlaucomaIndustryNewsletterRefractiveRegulationRetinaSurgical
September 2025 Ophthalmic News Briefs
The UK-based National Institute for Health and Care Excellence (NICE) announced Sept. 11 that it had approved idebenone (marketed as Raxone by Chiesi Pharmaceuticals) for the treatment of Leber her...
9/5/2025
BreakingCataractClinical TrialIOLSurgical
Ocumetics Implants First Patients in Trial of its Accommodating IOL
Ocumetics Technology, of Calgary, Canada, announced Aug. 18 that the first patients had been implanted in a clinical study of its accommodating intraocular lens (IOL). The company said the procedur...
8/22/2025
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Gives Green Light to Phase I/II Trial of Opus’ BEST1 Gene Therapy Candidate
Opus Genetics announced Aug. 18 that the US FDA had cleared its investigational new drug (IND) application for OPGx-BEST1, a gene therapy candidate targeting bestrophin-1 (BEST1)-related inherited ...
8/20/2025
Clinical TrialDealsMeetingNewsletterRetina
Cencora Steps into Major Role at ASRS Meeting Following Acquisition
The 2025 ASRS scientific meeting was a first for Cencora as an operator of clinical trials, but not for its subsidiary Retina Consultants of America (RCA). Cencora (formerly AmerisourceBergen), bet...
8/20/2025
Clinical TrialCornealDry EyeGene TherapyGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, August 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
8/20/2025
BiosimilarsClinical TrialDealsDry EyeEuropeGene TherapyGlaucomaIndustryInstrumentsLaserNewsletterRegulationRetinaSurgical
August 2025 Ophthalmic News Briefs
Glaukos announced during its earnings call on July 30 that it had acquired Mobius Therapeutics, of St. Louis, Missouri, whose lead compound, Mitosol, is the only FDA approved ophthalmic formulation...
8/15/2025
BreakingClinical TrialGlaucomaMIGSRegulationSurgical
Myra Vision Gains IDE Approval to Begin US Trial of Adjustable Glaucoma Shunt
Myra Vision announced Aug. 12 that the US FDA had issued a conditional approval letter for its investigational device exemption (IDE) application to initiate a US trial of its Calibreye titratable ...
8/8/2025
BreakingClinical TrialDealsGene TherapyRetina
Regenxbio Plans Pivotal Program for DR Gene Therapy, Amends Deal with AbbVie
Regenxbio announced Aug. 7 that it was planning a pivotal program for its suprachoroidal gene therapy candidate in diabetic retinopathy (DR)—along with a corresponding amendment to its collaboratio...
8/1/2025
BreakingClinical TrialPharmaRetina
Exonate Plans Phase IIb Trial of Retinal Eye Drop Candidate in NPDR
British company Exonate announced July 29 that it planned a Phase IIb clinical trial for lead compound EXN407, an eye drop candidate targeting retinal vascular diseases, in patients with non-prolif...
7/25/2025
BreakingClinical TrialDeviceGlaucoma
First Patient Treated in US Trial of Eyetronic Optic Nerve Therapy for Glaucoma
The Glaucoma Center of San Francisco announced July 21 that it had treated the first patient in the US as part of a clinical trial of Eyetronic, a non-invasive therapy to stimulate the optic nerve....
7/25/2025
BreakingClinical TrialDry Eye
Viatris’ Phase III Blepharitis Ointment Candidate Fails to Reach Primary Endpoint
Viatris announced July 18 that a Phase III trial of pimecrolimus 0.3% (MR-139) ophthalmic ointment in blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks ...
7/22/2025
Clinical TrialNewsletterRegulationRetina
Retina Researchers Urge J&J to File for Approval of XLRP Gene Therapy Despite Failed Trial
Investigators in the Phase III LUMEOS trial, with backing from the Foundation Fighting Blindness, issued a statement June 6 exhorting Johnson & Johnson to file for US FDA approval of bota-vec, a ge...
7/22/2025
Cell TherapyClinical TrialNewsletterRetina
OpRegen’s Phase I/IIa Trial in GA Shows Mean Improvement in VA Through 36 Months
Lineage Cell Therapeutics reported on June 23 that patients with geographic atrophy who were treated with OpRegen cell therapy in a Phase I/IIa clinical study showed mean improvement in visual acui...
7/22/2025
Clinical TrialNewsletterPresbyopia
Presbyopia Drop Candidate from Viatris and Opus Meets Endpoints in Second Phase III Trial
Commercial partners Viatris and Opus Genetics reported June 26 that their presbyopia drop candidate, MR-141 (phentolamine ophthalmic solution 0.75%), met its primary endpoint and key secondary endp...
7/22/2025
Cell TherapyClinical TrialCornealDry EyeGene TherapyGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, July 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
7/22/2025
Clinical TrialLaserNewsletterRetina
Iridex Reports Start of UK Trial Using MicroPulse with Anti-VEGF Injections in DME
Iridex reported June 24 that an independent, investigator-led UK study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy in diabetic macular edema (DME) had enrolled its first pat...
7/22/2025
BiosimilarsCataractCell TherapyChinaClinical TrialDealsDiagnosticDry EyeEuropeFundingFundusGene TherapyGlaucomaNewsletterPharmaPresbyopiaRegulationRetinaSurgical
July 2025 Ophthalmic News Briefs
Hoya Vision Care announced June 2 that it had acquired Centennial Optical, a Canadian distributor of ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories. Financial...
7/18/2025
BreakingCataractClinical TrialIOLSurgical
Ocumetics Set to Begin First-in-Human Study of its Accommodating IOL
Ocumetics Technology, of Calgary, Canada, announced June 24 that it was set to begin a first-in-human clinical study of its accommodating intraocular lens (IOL). The company said all the lenses for...
7/18/2025
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Gives Green Light to Trial of AAVantgarde’s Stargardt Gene Therapy Candidate
Italy’s AAVantgarde Bio announced July 15 that the US FDA had cleared the investigational new drug (IND) application for AAVB-039, its gene therapy candidate for Stargardt disease. The company said...
7/3/2025
BreakingClinical TrialLaserRetina
Iridex Reports Start of UK Trial Using MicroPulse with Anti-VEGF Injections in DME
Iridex reported June 24 that an independent, investigator-led UK study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy in diabetic macular edema (DME) had enrolled its first pat...
7/3/2025
BreakingClinical TrialRetina
OpRegen’s Phase I/IIa Trial in GA Shows Mean Improvement in VA Through 36 Months
Lineage Cell Therapeutics reported on June 23 that patients with geographic atrophy who were treated with OpRegen cell therapy in a Phase I/IIa clinical study showed mean improvement in visual acui...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.